Company profile: Siga Technologies
1.1 - Company Overview
Company description
- Provider of antiviral therapeutics for lethal pathogens, specializing in smallpox. Products include TPOXX (Tecovirimat-SIGA), approved for treatment of smallpox and, in various regions, monkeypox, cowpox, and vaccinia complications, and TPOXX Injection, an intravenous formulation for smallpox patients unable to swallow oral capsules.
Products and services
- Smallpox Therapeutic Development: Develops therapeutic products for smallpox, concentrating corporate effort on countermeasures against a lethal pathogen, pathogen-targeted
- TPOXX (Tecovirimat-SIGA): Produces an antiviral drug approved for treating smallpox and regionally for monkeypox, cowpox, and vaccinia complications, available as oral capsules, regulatory-approved
- TPOXX Injection: Delivers an intravenous formulation of tecovirimat for smallpox patients unable to swallow oral capsules, enabling parenteral administration in clinical settings, IV-form
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Siga Technologies
Turn Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceutical solutions to reduce the human and economic costs of infection and skin disease, including PermaFusion petrolatum-based liquid-in-oil suspension technology for high-bioavailability delivery; Hexagen FDA-cleared antimicrobial wound dressing; a pre-operative nasal decolonization program targeting MRSA; and onychomycosis treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Turn Therapeutics company profile →
Bioquell
HQ: United Kingdom
Website
- Description: Provider of biodecontamination systems and services specializing in Hydrogen Peroxide Vapor technology to eliminate bacteria, viruses, fungi, and spores. Products include Bioquell Hydrogen Peroxide Vapour Decontamination (35% H2O2 vapor for surface and airborne pathogen elimination), Rapid Bio-Decontamination Service, ProteQ automated room decontamination, and Qube isolators for sterility testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioquell company profile →
Trimeris
HQ: United States
Website
- Description: Provider of HIV research and drug discovery, founded in 1993 in Morrisville, North Carolina, whose early work led to an entirely new class of anti-HIV drugs called fusion inhibitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trimeris company profile →
Ondine Biomedical
HQ: Canada
Website
- Description: Provider of non-antibiotic, anti-infective therapies for bacterial, viral, and fungal infections, including Steriwave nasal decolonization that eradicates pathogens in minutes (MRSA, SARS-CoV-2), Photodisinfection using a photosensitive agent and non-thermal laser light to destroy pathogens without resistance, and an Expanded Access Program for investigational medicines prior to regulatory approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ondine Biomedical company profile →
Bugworks Research
HQ: India
Website
- Description: Provider of drug discovery focused on combating antimicrobial resistance (AMR) and small molecule cancer therapeutics, including BWC2094 targeting the adenosine pathway (CRC, NSCLC, TNBC, pancreas, prostate, RCC, HNSCC); ATM/DNA-PK dual inhibitors (BWC5036/BWC5089); BWC5044/BWC5077, BWC4496; spliceosome modulators/DNA damage agents; and ADC payload opportunities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bugworks Research company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Siga Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Siga Technologies
2.2 - Growth funds investing in similar companies to Siga Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Siga Technologies
4.2 - Public trading comparable groups for Siga Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →